Document is current
Any future updates will be listed below
-
Authors
Mäenpää, Matias
Jukema, Ruurt A.
van Diemen, Pepijn
Bär, Sarah
Raijmakers, Pieter G.
Sprengers, Ralf
Driessen, Roel S.
Bax, Jeroen J.
Knaapen, Paul
Knuuti, Juhani
Danad, Ibrahim
Saraste, Antti
Maaniitty, Teemu
-
Funding
Funding for this research was provided by:
InFLAMES Research Flagship
Cleerly inc.
Sydäntutkimussäätiö
The Research Council of Finland
Finnish State Research Funding
- License Information
-
More Information
Article History
Received: 3 September 2025
Accepted: 29 October 2025
First Online: 2 December 2025
Declarations
:
: The study was investigator-initiated and complies with the Declaration of Helsinki. The ethics committees of the Hospital District of Southwest Finland and Amsterdam University Medical Center approved the study protocol and waived the need for informed consent due to the retrospective nature and observational study design.
: Not applicable.
: Dr. Bär received research grants to the institution from Medis Medical Imaging Systems, Bangerter-Rhyner Stiftung (Basel, Switzerland) and Abbott, outside the submitted work, speaker fees from Cleerly inc. and travel fees from Sanofi. Dr. Knuuti received consultancy fees from GE Healthcare and Synektik and speaker fees from Siemens, outside of the submitted work. Dr. Saraste received consultancy fees from Astra Zeneca and Pfizer, and speaker fees from Abbott, Astra Zeneca, Janssen, Novartis and Pfizer. Dr. Bax received speaker fees from Abbott. Dr. Danad is a member of Cleerly Scientific Advisory Board. Dr. Knaapen has received research grants from Cleerly, Inc. and HeartFlow. Dr. Sprengers receive speaker fees from Boehringer-Ingelheim, Ferrer, MSD and Siemens, outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
